» Articles » PMID: 36741909

TREM2 As a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment

Overview
Journal Dis Markers
Publisher Wiley
Specialty Biochemistry
Date 2023 Feb 6
PMID 36741909
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The skin cutaneous melanoma (SKCM) is a devastating form of skin cancer triggered by genetic and environmental factors, and the incidence of SKCM has rapidly increased in recent years. Immune infiltration of the tumor microenvironment is positively associated with overall survival in many tumors. Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily and a crucial signaling hub for multiple pathological pathways that mediate immunity. Although numerous evidences suggest a crucial role for TREM2 in tumorigenesis of some tumors, no systematic SKCM analysis of TREM2 is available. . The relationship between TREM2 expression and diagnostic and prognostic value of SKCM patients via using The Cancer Genome Atlas (TCGA) data. The expression level of TREM2 and clinical characteristic correlation in SKCM patients were assessed by the Wilcoxon rank sum test. The cox regression methods, Kaplan-Meier (KM), and log-rank test were used to assess the impact of TREM2 expression on the overall survival (OS). Furthermore, the Gene Set Enrichment Analysis (GSEA) and TIMER were performed to evaluate the enrichment pathways and potential functions and quantify the immune cell infiltration level for TREM2 expression.

Results: The TREM2 in SKCM sample expression levels was significantly higher than in normal tissues. Moreover, this expression level of TREM2 was also associated with the BMI of SKCM patients. KM overall survival analysis and OS curve displayed that a high-level TREM2 expression was significantly correlated with a better SKCM prognosis of patients as compared with a low level of TREM2 expression. The GSEA analysis also revealed that TREM2 was associated with immune functions, such as neutrophil activation.

Conclusion: TREM2 played a crucial role in SKCM, which might be a prognostic biomarker and correlated with immune infifiltrates in SKCM patients.

Citing Articles

The Effect of Body Mass Index on Melanoma Biology, Immunotherapy Efficacy, and Clinical Outcomes: A Narrative Review.

Jansen J, Garmyn M, Guvenc C Int J Mol Sci. 2024; 25(12).

PMID: 38928137 PMC: 11204248. DOI: 10.3390/ijms25126433.


Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression.

Lei X, Gou Y, Hao J, Huang X Front Oncol. 2024; 14:1375729.

PMID: 38725629 PMC: 11079285. DOI: 10.3389/fonc.2024.1375729.


Deciphering the molecular and clinical characteristics of TREM2, HCST, and TYROBP in cancer immunity: A comprehensive pan-cancer study.

Zheng P, Tan Y, Liu Q, Wu C, Kang J, Liang S Heliyon. 2024; 10(5):e26993.

PMID: 38468942 PMC: 10926084. DOI: 10.1016/j.heliyon.2024.e26993.

References
1.
Abbas O, Miller D, Bhawan J . Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol. 2014; 36(5):363-79. DOI: 10.1097/DAD.0b013e31828a2ec5. View

2.
Bouchon A, Cella M, Colonna M . A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. 2001; 194(8):1111-22. PMC: 2193511. DOI: 10.1084/jem.194.8.1111. View

3.
Fridman W, Pages F, Sautes-Fridman C, Galon J . The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12(4):298-306. DOI: 10.1038/nrc3245. View

4.
Cheng X, Wang X, Nie K, Cheng L, Zhang Z, Hu Y . Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Front Immunol. 2021; 12:646523. PMC: 7925850. DOI: 10.3389/fimmu.2021.646523. View

5.
Zhou M, Zhang Z, Zhao H, Bao S, Cheng L, Sun J . An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme. Mol Neurobiol. 2017; 55(5):3684-3697. DOI: 10.1007/s12035-017-0572-9. View